Arrowhead shares jump over 21% after late-stage plozasiran trial results

Positive data in severe hypertriglyceridemia prompted Chardan Capital to raise its price target, highlighting stronger market confidence in the drug candidate.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.